Loading
A phase 1/2 trial of Sonrotoclax, Dexamethasone, Carfilzomib in multiple myeloma, run by BeOne Medicines, now recruiting.
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma is a phase 1/2 interventional study registered as NCT04973605 by BeOne Medicines, with 246 participants planned, started 2021-09-16 and due to reach its primary completion in 2026-11. Interventions recorded: Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide. Conditions listed: Relapsed/Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, Daratumumab, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/